Center for Genomic Medicine, Massachusetts General Hospital, Boston, MA, USA.
Department of Pathology, Massachusetts General Hospital, Boston, MA, USA.
Nat Biotechnol. 2023 Mar;41(3):409-416. doi: 10.1038/s41587-022-01492-y. Epub 2022 Oct 6.
Methods for in vitro DNA cleavage and molecular cloning remain unable to precisely cleave DNA directly adjacent to bases of interest. Restriction enzymes (REs) must bind specific motifs, whereas wild-type CRISPR-Cas9 or CRISPR-Cas12 nucleases require protospacer adjacent motifs (PAMs). Here we explore the utility of our previously reported near-PAMless SpCas9 variant, named SpRY, to serve as a universal DNA cleavage tool for various cloning applications. By performing SpRY DNA digests (SpRYgests) using more than 130 guide RNAs (gRNAs) sampling a wide diversity of PAMs, we discovered that SpRY is PAMless in vitro and can cleave DNA at practically any sequence, including sites refractory to cleavage with wild-type SpCas9. We illustrate the versatility and effectiveness of SpRYgests to improve the precision of several cloning workflows, including those not possible with REs or canonical CRISPR nucleases. We also optimize a rapid and simple one-pot gRNA synthesis protocol to streamline SpRYgest implementation. Together, SpRYgests can improve various DNA engineering applications that benefit from precise DNA breaks.
方法体外 DNA 切割和分子克隆仍然无法精确地切割直接相邻碱基的 DNA。限制酶 (REs) 必须结合特定的模体,而野生型 CRISPR-Cas9 或 CRISPR-Cas12 核酸酶需要前导序列相邻基序 (PAMs)。在这里,我们探索了我们之前报道的近 PAM 缺失的 SpCas9 变体 SpRY 的实用性,将其用作各种克隆应用的通用 DNA 切割工具。通过使用超过 130 种靶向各种 PAMs 的向导 RNA (gRNA) 进行 SpRY DNA 消化 (SpRYgests),我们发现 SpRY 在体外无 PAM,并且可以在几乎任何序列上切割 DNA,包括对野生型 SpCas9 切割具有抗性的位点。我们说明了 SpRYgests 的多功能性和有效性,以提高几种克隆工作流程的精度,包括那些无法使用 REs 或规范的 CRISPR 核酸酶进行的工作流程。我们还优化了一种快速简单的 gRNA 合成方案,以简化 SpRYgest 的实施。总之,SpRYgests 可以改进受益于精确 DNA 断裂的各种 DNA 工程应用。